Sodium thiosulfate for the treatment of warfarin‑induced calciphylaxis in a nondialysis patient
Emily J. Carrell1★, Allison Bell1★ Corresponding author
- 1Department of Pharmacy Practice, The University of Mississippi School of Pharmacy, Jackson, Mississippi, USA.
CORRESPONDENCE
Emily J. Carrell
Department of Pharmacy Practice, The University of Mississippi School of Pharmacy, Jackson, Mississippi, USA.
Received: 24-11-2014; Revised: 24-11-2014; Accepted: 09-04-2015.
Volume 6, Issue 4 · pp. 222–224 · PUBLISHED 2015 · DOI: 10.4103/0976-500X.171882
View on J Pharmacol. Pharmacother. original site ↗
ABSTRACT
Calciphylaxis or uremic arteriolopathy is a complex process typically seen in patients with end‑stage renal disease, but has also been reported in patients with normal renal function. However, therapies for calciphylaxis are based on reports of traditional patients (i.e., end‑stage renal disease). A mainstay of therapy, sodium thiosulfate (STS), has been shown to be effective for the treatment of calciphylaxis. Without a standardized therapy reported for nondialysis patients there is a need for evidence‑based therapy. Here, we report a case of a 63‑year‑old woman with an acute injury on chronic kidney disease (CrClBaseline = 48 mL/min, CrClAKI = 36 mL/min), not requiring dialysis, with warfarin‑induced calciphylaxis. After 4 weeks of therapy with STS, sevelamer, alendronate, and enzymatic debridement the patient subjectively reported slight improvement of the necrotic ulcers but developed cellulitis on her nonaffected limb. Additionally, after 12 weeks of therapy she was readmitted for renal failure and subsequently required dialysis.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Carrell, E. J., & Bell, A. (2015). Sodium thiosulfate for the treatment of warfarin‑induced calciphylaxis in a nondialysis patient. Journal of Pharmacology and Pharmacotherapeutics, 6(4), 222–224. https://doi.org/10.4103/0976-500X.171882